Toshiyuki Isoe
Hokkaido University Hospital(JP)
Publications by Year
Research Areas
Angiogenesis and VEGF in Cancer, Colorectal Cancer Treatments and Studies, Gastric Cancer Management and Outcomes, Microbial Natural Products and Biosynthesis, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.(1990)
- → Novel Potent Orally Active Selective VEGFR-2 Tyrosine Kinase Inhibitors: Synthesis, Structure−Activity Relationships, and Antitumor Activities of N-Phenyl-N‘-{4-(4-quinolyloxy)phenyl}ureas(2005)144 cited
- → Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors(2011)107 cited
- → A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model(2006)99 cited
- → KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth(2004)66 cited
- Suppression of experimental lung colonization of a metastatic variant of murine colon adenocarcinoma 26 by a monoclonal antibody 8F11 inhibiting tumor cell-induced platelet aggregation.(1991)
- → Structure-antitumor activity relationship of semi-synthetic spicamycin analogues.(1993)34 cited
- Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells.(1991)
- → Anti‐tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model(2008)34 cited
- Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells.(1994)